Organization & Developments: Phase Scientific

Parents

*2025: Company has distributed more than 100 million tests in over 30 countries and conducted over 8 million laboratory tests worldwide.
*Company developing a comprehensive suite of non-invasive tests for early detection of cancers, women's health conditions, and infectious diseases.
*Company's test Phasify uses urine concentration technology for molecular diagnostics, allowing for multi-cancer detection.
*Developing urine-based diagnostics tests for early disease detection
*PHASIFY™ is the world's first urine concentration technology designed for molecular diagnostics, setting a new industry benchmark by capturing approximately 10 times more target analytes from urine specimens compared to the current gold standard.
*This proprietary innovation uniquely positions PHASE Scientific as the only player in the urine-based liquid biopsy diagnostics field, with proven clinical performance for multi-cancer detection.
*Unlike traditional invasive screening methods, PHASIFY™ enables convenient, at-home sample collection, empowering proactive health management and preventive care.
2025: Since its founding, the company has been supported by Gates Foundation, US governmental agencies National Science Foundation and National Institute of Health, Ministry of Science and Technology of China, Hong Kong Innovation, Technology and Industry Bureau and Hong Kong Science and Technology Parks.